Read publications from Enrich staff on the following topics:
These two disciplines have some things in common, but require a different decision frame and different analytical toolkits.
During periods of cost cutting, resist the temptation to delay tough decisions and seize the opportunity to perform a strategic portfolio assessment. In this article we suggest several levels, in increasing order of difficulty, at which a strategic review can be accomplished.
The use of dashboards has been spreading throughout organizations, but are not yet widespread within Portfolio Management. We suggest ways that dashboards can enhance portfolio processes and offer tips and suggestions for creating effective project and portfolio dashboards.
Portfolios of Early-Stage projects present a set of unique challenges that require different approaches than Late-Stage portfolios. We suggest approaches for addressing these differences and ensuring alignment. Presented at the Center for Business Intelligence's Early Stage Asset Valuation and Evaluations to Phase I Conference, San Francisco, CA, 3/2008.
Listen to anyone speak about Portfolio Management for more than five minutes, and you're liable to hear them bandy about the term "efficient frontier." They're very commonly used in portfolio processes...at least most people think. We discuss the difference between an Efficient Frontier and a Productivity Ranking and suggest appropriate usages for each.
A discussion on the most common weaknesses found in Strategic Portfolio Management processes and solutions on how to address them. Presented at the Cambridge Healthtech Institute's Portfolio Management Conference: "Creating a Portfolio for Optimal Productivity", Philadelphia, PA, 11/2007.
A series of case studies on using Portfolio Management as the link between between strategy and execution. Co-presented with Stuart Pavelin of Kinapse, a London-based partner of Enrich. Presented at the Marcus Evans 7th Annual Project and Portfolio Management Conference for Pharma: "Effective Organisation and Decision-Making for Long-Term Growth", Amsterdam, Netherlands, 11/2007.
A discussion of the impact of high-impact, low-probabilty events on R&D portfolios. Inspired by the book The Black Swan by Nassim Taleb. Published on the Enrich Consulting website, 11/2007.
Download our paper summarizing eight rules for effective portfolio management.
An outline of techniques for holding productive, high-level discussions with decision-makers, and methods for the selection of the best portfolio for the organization. Presented at the Strategic Research Institute's Portfolio Innovations Conference, San Francisco, CA, 2/2007.
A discussion of why traditional portfolio management methods fall short and ways to improve upon them. Presented at the Cambridge HealthTech Institute's Resource Planning and Portfolio Management Conference in Philadelphia, PA, 11/2006.
Suggestions for moving from Operational to Strategic Portfolio Management, and how optimization might be used to aid the transition. Presented at Marcus Evans' 6th Annual Project and Portfolio Management for Pharma: "Optimising Strategies to Maximise Efficiency & Productivity", Berlin, Germany, 10/2006.
Lessons for getting (and keeping) management attention to power the portfolio process and enable strategic decision-making. Presented at the 11th Annual Strategic & Operational Portfolio Management Conference, co-produced by IIR & PDMA, in Ft. Lauderdale, FL, 2/2006.
A proposal that analysis should be simplified in order to ensure transparency and organizational buy-in. Presented at the Decision Analysis Affinity Group annual meeting in Philadelphia, PA, 4/2005.
Presentation of the key building blocks of portfolio management, without which processes cannot be successful. Presented at the Strategic Research Institute's Conference on Pharma and Biotech Portfolio Management, in San Diego, CA, 3/2004.
Discussion of strategies for linking the R&D and Marketing organizations, with particular emphasis on categorizing risk. Presented at the Cambridge Healthtech Institute conference on Intelligent Drug Discovery and Development, Philadelphia, PA, 5/2003.
An overview of an approach to managing the intersection of Operational and Strategic Portfolio Management. Includes suggestions on identifying, forecasting, and managing resource bottlenecks.
Methods for linking Portfolio Management to other business processes within the organization, with particular emphasis on Strategic Planning and Business Development. Presented at SMI Pharmaceutical Portfolio and Life Cycle Management Conference, London, UK, 6/2006.
Techniques for addressing risk when generating forecasts for projects in New Product Development. Presented at Joint Statistical Meeting of the American Statistical Association in San Francisco, CA, 8/2003.
Allergan and Enrich discuss how Allergan uses the Enrich Portfolio System to help align its strategic processes. Presented at the Strategic Research Institute's Pharma/Biotech Portfolio Management Conference in Philadelphia, PA, 1/2006.
Johnson & Johnson and Enrich discuss how J&J addressed significant changes to their portfolio management processes along side implementation of the Enrich Portfolio System. Presented at the Barnett International Portfolio Management Conference in Philadelphia, PA, 3/2005.
Nektar and Enrich discuss how considering project licensing alternatives was critical to the success of Nektar's portfolio process. Presented at Strategic Research Institute's Conference on Pharmaceutical and Biotech Portfolio Management, in Philadelphia, PA, 1/2005.
Roche and Enrich explain how working the process was paramount as Roche revamped its portfolio management process. Presented at Barnett International Portfolio Management Conference in Philadelphia, PA, 11/2003.
A detailed discussion of the new product development process currently in use by WL Gore and Associates. Includes information on the methods used by Gore for project valuation, uncertainty analysis, and sensitivity analysis. Published in the Journal of Business Forecasting, Summer 2003.
Isis and Enrich review how licensing alternatives and corporate finance played key roles in the evaluation of Isis' portfolio. Presented at Strategic Research Institute's Rx & Biotech Portfolio Management Conference, La Jolla, California, 3/2003.